New York City, NY – According to filings with the U.S. Securities and Exchange Commission, Petra Pharma is raising $27,545,484.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Brian OCallaghan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Petra Pharma

Petra is a leading clinical-stage pharmaceutical company developing a diverse portfolio of novel therapies that modulate phosphoinositide (PI) signaling pathways for the treatment of cancer. Petra is exploring new frontiers in PI signaling pathways to introduce next-generation lipid kinase inhibitors that offer the potential to address the many tumors characterized by PI pathway dysregulation. Armed with a refined understanding of these pathways, Petra is advancing a diverse portfolio of therapies for the patients most in need of them.

To learn more about Petra Pharma, visit http://petrapharmacorp.com/

Contact:
Brian OCallaghan, President and Chief Executive Officer
206-957-7300
bocallaghan@petrapharmacorp.com
https://www.linkedin.com/in/brian-o-callaghan-43459a16/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved